- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01114750
A Study to Determine the Absorption of Peroral Insulin in Dextran Matrix (ORA3) (ORA3)
October 3, 2010 updated by: Bows Pharmaceuticals AG
A Placebo-controlled Study of Insulin Absorption in Healthy Volunteers After Single-dose Oral Administration of Insulin in Dextran Matrix
A pharmacokinetic study on the absorption of perorally delivered insulin in dextran matrix after single dose administration.
Study Overview
Status
Suspended
Conditions
Intervention / Treatment
Detailed Description
The study is a single blind, cross over study where each subject will receive a a single active dose (200 IU) of insulin in dextran matrix and placebo on two different experimental days.
Study Type
Interventional
Enrollment (Anticipated)
8
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Stockholm, Sweden
- Karolinska Trial Alliance (KTA), Phase I Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy male subjects, age 18-40 years.
- Fasting blood glucose within the range 4.0-6.0 mmol/L at Screening, and on Day 1 before dosing ≥ 4 mmol/L. However, the subject should not be excluded from the study if the blood glucose is out of this range once the treatment period has started.
- Body Mass Index (BMI) of 20-27 kg/m2
- Medically stable as determined by history and physical examination, including vital signs.
- Screening laboratory tests must be within normal range or judged as not clinically significant by Principal investigator/Subinvestigator.
- Negative urine ketoacidosis test
- ECG including QTcB shows no clinically significant abnormality or acute ischemia
- Supine BP ≤ 139/89 mm Hg diastolic/systolic, or at the discretion of the investigator
- Able to adhere to the study visit schedule, and to understand and comply with other protocol requirements.
- Capable of giving informed consent, which must be obtained prior to any screening procedures.
- Negative laboratory screen for Hepatitis B (HBsAg and anti-HBc antibodies), Hepatitis C (anti HCV) and HIV (1&2).
- Willing to refrain from consuming alcohol 48 hours prior to dosing and throughout the period of sample collection.
- Not on any prohibited medication (See section 8.9), or at the discretion of the investigator.
Exclusion Criteria:
- Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease, or any other condition which increases risk of participation in this trial in the opinion of the investigator.
- Currently known malignancy or a history of malignancy within the previous 5 years, with the exception of basal cell or squamous cell carcinoma of the skin that has been excised more than one year ago with no evidence of recurrence
- A chronic or recurrent infectious disease, including but not limited to, chronic renal infection, chronic chest infection (bronchiectasis), sinusitis, recurrent urinary tract infection (recurrent pyelonephritis or chronic nonremitting cystitis), open skin wound, or ulcer.
- Other medical conditions, drug treatments or significant medical problems that would preclude participation in a clinical trial that, in the opinion of the investigator, disqualifies the subject.
- Participation in a clinical trial within the prior 3 months
- History of GI surgery (other than appendectomy) or known GI motility disorders.
- History of a serious infection, including but not limited to hepatitis, pneumonia, or pyelonephritis, or have been hospitalized or received intravenous antibiotics for an infection, during the previous two months.
- A recent adult history of clinically significant allergic reaction to any drug.
- History of polyps in the gastrointestinal tract.
- Known to have had a substance abuse (drug or alcohol) problem within the previous 5 years
- Alcohol use within 48 hours prior to visits to the study unit.
- Unable to undergo venipunctures for study purposes because of poor tolerability or lack of easy access.
- Engaging in any strenuous exercise (such as running or weight lifting or playing any team sports such as soccer) within 48 hours prior to visits to the study unit.
- Donation of plasma within 7 days prior to the first dose.
- Donation of blood within 3 months prior to the first dose
- Difficulty in swallowing capsules.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Oral Insulin in Dextran Matrix
A group consisting of male healthy volunteers will be given placebo and one single dose of insulin in dextran matrix, for estimation of post-dose relative bioavailability.
|
Single dose capsule (and placebo)
|
Placebo Comparator: Placebo
A group consisting of male healthy volunteers will be given placebo and one single dose of insulin in dextran matrix, for estimation of post-dose relative bioavailability.
|
Single dose capsule (and placebo)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic variable: insulin
Time Frame: 3-5 hours
|
Estimation of insulin AUC and Cmax post dose-administration
|
3-5 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nabil Al-Tawil, M.D.; Ph.D., Karolinska Trial Alliance, Stockholm
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Primary Completion (Anticipated)
August 1, 2010
Study Completion (Anticipated)
October 1, 2010
Study Registration Dates
First Submitted
April 29, 2010
First Submitted That Met QC Criteria
April 30, 2010
First Posted (Estimate)
May 3, 2010
Study Record Updates
Last Update Posted (Estimate)
October 5, 2010
Last Update Submitted That Met QC Criteria
October 3, 2010
Last Verified
October 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ORA3-2010-019098-14
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on Insulin in dextran matrix capsule (and placebo)
-
Bows Pharmaceuticals AGSuspended
-
CytokineticsCompletedHealthy Subjects | Symptomatic Obstructive Hypertrophic CardiomyopathyUnited States
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
The Baruch Padeh Medical Center, PoriyaUnknown
-
University of Illinois at ChicagoNational Heart, Lung, and Blood Institute (NHLBI)CompletedStress, Psychological | Iron-deficiency | Pregnancy, High RiskUnited States
-
Oramed, Ltd.IntegriumCompletedDiabetes Mellitus, Type 2 | NASH - Nonalcoholic SteatohepatitisUnited States, Israel
-
Biocon LimitedCompletedType 2 Diabetes Mellitus
-
University of OxfordRecruitingMalaria | Plasmodium FalciparumUnited Kingdom
-
Joseph B. Ciolino, MDUnited States Department of DefenseCompletedKeratolysisUnited States
-
Hospital Civil de GuadalajaraActive, not recruitingAcute Kidney Injury | Anemia, Iron DeficiencyMexico